The intranasal foralumab platform is highlighted as the only fully human anti-CD3 monoclonal antibody in clinical exploration, with potential implications for neurodegenerative and neuroinflammatory diseases such as Alzheimer's disease and multiple sclerosis.

Tiziana notes ongoing clinical activity in na-SPMS, with 14 patients in the Expanded Access Program showing improvement or stability within six months.

CEO Ivor Elrifi emphasizes the broader potential of foralumab, including MS, Alzheimer's, and ALS, and cites favorable safety signals from earlier intranasal foralumab data in non-active secondary progressive MS.

Tiziana highlights prior safety signals and clinical responses in expanded access for NA-SPMS and ongoing Phase 2a trial (NA-SPMS, NCT06292923).

TLSA’s stock sits around $1.34, with a 52-week rise of about 66%, signaling positive market sentiment.

The stock moved higher on the news, roughly 5%–6% intraday, as investors weighed mechanistic relevance and potential future clinical development despite early, non-peer-reviewed data.

The full preprint is available on bioRxiv and has not undergone peer review yet.

The Form 6-K includes a press release and the bioRxiv preprint detailing the Long COVID study, which remains unreviewed.

Analysts caution that TLSA is a clinical-stage biotech with encouraging preclinical signals but no revenue or earnings yet, advising readers to consider risk alongside potential.

Investors are encouraged to review TLSA’s stock page and screening tools for context on early-stage opportunities and risks.

The report ties preclinical data, early clinical signals, ongoing trials, and recent financing into Tiziana’s broader neurology-focused strategy.

Experts note a broad therapeutic window for intranasal foralumab, with activity in early and late stages after infection and no detrimental impact on antiviral immunity.